Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Ramón Palmero et al.|The Lancet Oncology|2012Cited by 5.5k
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized TrialC. Gridelli, Vittorio Gebbia|JNCI Journal of the National Cancer Institute|2003Cited by 795
Author Index Vol. 77, Suppl. 1, 2009Antônio Rossi, Sabino De Placido, Domenico Galetta et al.|Oncology|2009Cited by 0